RAC are also investigating drug combinations in the melanoma pre-clinical (which were not mentioned in the interim results). So we can expect something entirely new in the final results:
The market for Melanoma is dominated by Yervoy (targets CTLA-4) and Opdivo (targets PD-1). It it is expected that PD-1 checkpoint immunotherapy will dominate the market by 2026. https://www.thepharmaletter.com/article/melanoma-drug-sales-set-to-rise-at-5-3-cagr
And, from the investor presentation we know that RAC are specifically looking for PD-1 synergies in melanoma.
RAC are also investigating drug combinations in the melanoma...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |